892TiPKEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
Graff, J N, Burgents, J, Liang, L W, Stenzl, AVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz248.049
Date:
October, 2019
File:
PDF, 76 KB
2019